Logo image of CING

CINGULATE INC (CING) Stock Fundamental Analysis

NASDAQ:CING - Nasdaq - US17248W3034 - Common Stock - Currency: USD

5.66  +0.49 (+9.48%)

After market: 5.72 +0.06 (+1.06%)

Fundamental Rating

1

CING gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. CING has a bad profitability rating. Also its financial health evaluation is rather negative. CING does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CING has reported negative net income.
In the past year CING has reported a negative cash flow from operations.
In the past 5 years CING always reported negative net income.
In the past 5 years CING always reported negative operating cash flow.
CING Yearly Net Income VS EBIT VS OCF VS FCFCING Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -131.33%, CING is not doing good in the industry: 80.93% of the companies in the same industry are doing better.
CING has a worse Return On Equity (-276.12%) than 74.23% of its industry peers.
Industry RankSector Rank
ROA -131.33%
ROE -276.12%
ROIC N/A
ROA(3y)-311.2%
ROA(5y)-229.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CING Yearly ROA, ROE, ROICCING Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CING so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CING Yearly Profit, Operating, Gross MarginsCING Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

CING has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CING has less shares outstanding
CING has a better debt/assets ratio than last year.
CING Yearly Shares OutstandingCING Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CING Yearly Total Debt VS Total AssetsCING Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

CING has an Altman-Z score of -14.27. This is a bad value and indicates that CING is not financially healthy and even has some risk of bankruptcy.
CING has a Altman-Z score of -14.27. This is in the lower half of the industry: CING underperforms 76.80% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that CING is somewhat dependend on debt financing.
CING has a Debt to Equity ratio of 0.85. This is in the lower half of the industry: CING underperforms 69.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z -14.27
ROIC/WACCN/A
WACCN/A
CING Yearly LT Debt VS Equity VS FCFCING Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

CING has a Current Ratio of 1.87. This is a normal value and indicates that CING is financially healthy and should not expect problems in meeting its short term obligations.
CING's Current ratio of 1.87 is on the low side compared to the rest of the industry. CING is outperformed by 62.37% of its industry peers.
A Quick Ratio of 1.87 indicates that CING should not have too much problems paying its short term obligations.
CING has a Quick ratio of 1.87. This is comparable to the rest of the industry: CING outperforms 40.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.87
CING Yearly Current Assets VS Current LiabilitesCING Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.99% over the past year.
EPS 1Y (TTM)95.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.80% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.94%
EPS Next 2Y36.5%
EPS Next 3Y25.51%
EPS Next 5Y21.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CING Yearly Revenue VS EstimatesCING Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
CING Yearly EPS VS EstimatesCING Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CING reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CING is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CING Price Earnings VS Forward Price EarningsCING Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CING Per share dataCING EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as CING's earnings are expected to grow with 25.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3Y25.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CING!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CINGULATE INC

NASDAQ:CING (7/21/2025, 8:00:00 PM)

After market: 5.72 +0.06 (+1.06%)

5.66

+0.49 (+9.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners3.22%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap24.05M
Analysts82
Price Target29.58 (422.61%)
Short Float %4.71%
Short Ratio1.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-86.5%
Min EPS beat(2)-171.8%
Max EPS beat(2)-1.2%
EPS beat(4)2
Avg EPS beat(4)-36%
Min EPS beat(4)-171.8%
Max EPS beat(4)24.09%
EPS beat(8)4
Avg EPS beat(8)-23.33%
EPS beat(12)6
Avg EPS beat(12)-12.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.69%
PT rev (3m)-18.08%
EPS NQ rev (1m)1.58%
EPS NQ rev (3m)2.75%
EPS NY rev (1m)1.09%
EPS NY rev (3m)-9.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.06
P/tB 4.06
EV/EBITDA N/A
EPS(TTM)-12.36
EYN/A
EPS(NY)-2.53
Fwd EYN/A
FCF(TTM)-3.4
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -131.33%
ROE -276.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-311.2%
ROA(5y)-229.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.87
Altman-Z -14.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)36.45%
Cap/Depr(5y)56.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.56%
EPS Next Y82.94%
EPS Next 2Y36.5%
EPS Next 3Y25.51%
EPS Next 5Y21.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.25%
OCF growth 3YN/A
OCF growth 5YN/A